Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01607619 · ClinicalTrials.gov registry record · NA

Effect of Anatabine on Elevated Blood Levels of C-reactive Protein

A NA study of Inflammation, sponsored by Roskamp Institute.

Completed
Registry status
NA
Development phase
117
Enrollment target
3
Study locations

NCT01607619 is a NA study of Inflammation that has completed, run by Roskamp Institute. The registered enrollment target is 117 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01607619, a NA study of Inflammation, has completed, sponsored by Roskamp Institute.

COMPLETED
Registry status
NA
Development phase
117 participants
Enrollment target
3
Study locations

Study Summary

The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. Therefore the investigators are looking for volunteers with high blood levels of C-reactive Protein (CRP) and will monitor the blood CRP levels at several time points throughout the study.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Anatabine

Study Locations (3)

Michigan

  • McLaren Community Medical Center - Flint
  • Medical Practice - Shelby

Florida

  • The Roskamp Institute, Inc. - Sarasota

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2011-05
Est. Completion 2013-01
Phase NA

Sponsor

Roskamp Institute

7 total trials

What the Registry Record Tells You About NCT01607619

The ClinicalTrials.gov registry entry for NCT01607619 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The listed sponsor is Roskamp Institute, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Anatabine is the first listed.

NCT01607619 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Florida.

Frequently Asked Questions

What is clinical trial NCT01607619 about?

NCT01607619 is a clinical study titled "Effect of Anatabine on Elevated Blood Levels of C-reactive Protein". The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of hi...

What is the current status of trial NCT01607619?

This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2011-05. Estimated completion is 2013-01.

What conditions does trial NCT01607619 study?

This clinical trial studies the following conditions: Inflammation.

What interventions are being tested in trial NCT01607619?

The interventions under investigation include: Anatabine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01607619?

This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01607619 being conducted?

This trial has 3 study locations across Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.